豐原藥業(000153.SZ):控股股東及其一致行動人擬將所持5.10%股份協議轉讓給貴和達毅
格隆匯8月11日丨豐原藥業(000153.SZ)公佈,公司控股股東安徽豐原集團有限公司(簡稱“豐原集團”)及其一致行動人馬鞍山豐原企業管理有限公司(簡稱“馬鞍山豐原”)擬通過協議轉讓方式,向海南貴和達毅投資合夥企業(有限合夥)(簡稱“貴和達毅”)轉讓其持有的公司股份合計23,698,554股,佔公司總股本的5.10%。轉讓價格爲6.72元/股,股份轉讓總價款合計爲人民幣1.59億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.